You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK)購美藥廠新一代氨基糖(甘)類抗生素之大中華區權益
阿思達克 02-20 16:49
四環醫藥(00460.HK)公布,附屬全資子公司「軒竹」已收購於美國特拉華州註冊成立的公司Achaogen於大中華區(包括中國內地及港澳台)有關新一代氨基糖(甘)類抗生素plazomicin的所有權益及知識產權。 Plazomicin是由Achaogen開發的新一代半合成氨基糖(甘)類抗生素,主要通過與細菌核糖體30S亞基結合,產生抑菌作用,開發用於治療多藥耐藥(MDR)革蘭氏陰性菌腸杆菌科細菌導致的嚴重感染,包括對碳青霉烯類抗生素耐藥的腸杆菌。在中國,MDR菌感染途徑主要為醫院獲得性感染,受感染者多為各種原因導致的免疫力低下者。如新型冠狀病毒等病毒感染後,會侵犯淋巴細胞破壞人體的免疫系統,當人體的免疫力降低時便有可能出現繼發細菌感染,增加醫院獲得性進一步感染機會。 據醫藥市場調研機構Evaluate Pharma預測,plazomicin的年銷售額在2022年將達到3.13億美元。而在大中華區上市後,集團預期plazomicin將帶來可觀的經濟收益。(ic/da)~ 阿思達克財經新聞 網址: www.aastocks.com
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account